| Company Name: |
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
|
| Tel: |
17702719238 |
| Email: |
sales@sun-shinechem.com |
| Products Intro: |
Product Name:BIT-225
CAS:917909-71-8
Purity:98% HPLC Package:50.0mg;100.0mg; 200.0mg;500mg;1g;5g; 10g
|
|
| Product Name: | BIT225 | | Synonyms: | BIT225;N-(Aminoiminomethyl)-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthalenecarboxamide;N-[5-(1-Methyl-1H-pyrazol-4-yl)-naphthalene-2-carbonyl]-guanidine;EOS-60377;2-Naphthalenecarboxamide, N-(aminoiminomethyl)-5-(1-methyl-1H-pyrazol-4-yl)-;N-Carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide | | CAS: | 917909-71-8 | | MF: | C16H15N5O | | MW: | 293.32 | | EINECS: | | | Product Categories: | | | Mol File: | 917909-71-8.mol |  |
| | BIT225 Chemical Properties |
| solubility | DMSO:0.0(Max Conc. mg/mL);0.0(Max Conc. mM) | | form | Solid | | color | Off-white to light yellow |
| | BIT225 Usage And Synthesis |
| Uses | BIT-225 is an inhibitor for Vpu protein through block of Vpu ion channel, and thus inhibits the release of HIV-1, especially in monocyte-derived macrophages (EC50 is 2.25 μM), without significant cytotoxicity (TC50 is 284 μM)[1]. | | References | [1] Khoury G, et al., Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob Agents Chemother. 2010 Feb;54(2):835-45. DOI:10.1128/AAC.01308-09 |
| | BIT225 Preparation Products And Raw materials |
|